Racura Oncology Ltd (ASX:RAC)
2.420
+0.040 (1.68%)
Feb 26, 2026, 2:03 PM AEST
Racura Oncology Revenue
In the fiscal year ending June 30, 2025, Racura Oncology had annual revenue of 6.04M AUD with 24.96% growth. Racura Oncology had revenue of 788.42K in the half year ending June 30, 2025, a decrease of -56.50%.
Revenue
6.04M
Revenue Growth
+24.96%
P/S Ratio
71.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
432.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 6.04M | 1.21M | 24.96% |
| Jun 30, 2024 | 4.84M | 1.70M | 54.29% |
| Jun 30, 2023 | 3.13M | 2.43M | 342.83% |
| Jun 30, 2022 | 707.81K | 320.42K | 82.71% |
| Jun 30, 2021 | 387.39K | 228.01K | 143.07% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 95.02M |
| PYC Therapeutics | 21.84M |
| Starpharma Holdings | 14.58M |
| Clarity Pharmaceuticals | 9.46M |
| Orthocell | 7.55M |
| Recce Pharmaceuticals | 7.51M |
| Dimerix | 5.59M |
| Actinogen Medical | 5.49M |